Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428320 | 1.00 | BTK (0.48) | BTKEPHX2RENGAACTSK | |
| SCHEMBL26607406 | 1.00 | BTK (0.48) | BTKEPHX2RENGAACTSK | |
| SCHEMBL20497903 | 1.00 | BTK (0.48) | BTKEPHX2RENGAACTSK | |
| SCHEMBL25816286 | 1.00 | BTK (0.48) | BTKEPHX2RENGAACTSK | |
| SCHEMBL5390795 | 0.90 | BTK (0.53) | BTKEPHX2RENGAACTSK | |
| SCHEMBL5376383 | 0.90 | BTK (0.53) | BTKEPHX2RENGAACTSK | |
| SCHEMBL5390787 | 0.90 | BTK (0.53) | BTKEPHX2RENGAACTSK | |
| SCHEMBL1710195 | 0.90 | BTK (0.53) | BTKEPHX2RENGAACTSK | |
| SCHEMBL114920 | 0.86 | BTK (0.51) | BTKEPHX2RENGAACTSK | |
| Hydrochloric Acid SCHEMBL222511 | 0.84 | BTK (0.50) | BTKEPHX2RENGAACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368192-A1 | Nitrogen-Containing Heterocyclic Compound, and Preparation Method Therefor, Intermediate Thereof, and Application Thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4365178-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | Shanghai Allist Pharmaceuticals Co., Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368192-A1 | Nitrogen-Containing Heterocyclic Compound, and Preparation Method Therefor, Intermediate Thereof, and Application Thereof | KRAS, NRAS, HRAS | BTK 1566/4885EPHX2 2566/4885REN 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.